Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

2025 Leerink Partners 2025 Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 11, 2025 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https ...

Regeneron Pharmaceuticals announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for linvoseltamab, an investigational treatment for adult patients with ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...